Eli Lilly to present new Kisunla and Alzheimer’s blood-test data at AAIC 2026

Eli Lilly plans to present new data related to its Alzheimer’s disease program at the 2026 Alzheimer’s Association International Conference (AAIC), according to a report published July 11 by Yahoo Finance. The presentation is expected to include additional long-term results for Kisunla, as well as updated safety information.

Kisunla, which is also known by its generic name donanemab-azbt, is Lilly’s anti-amyloid therapy intended to address a core biological feature of Alzheimer’s disease. While the specific study designs and endpoints were not detailed in the July 11 report, Lilly is indicating that it will extend its public data beyond earlier results.

In addition to Kisunla-related findings, Lilly said it would share information connected to an Alzheimer’s blood test at AAIC. The reported focus suggests the company is working to strengthen how Alzheimer’s is detected and monitored, using blood-based markers rather than relying solely on imaging or cerebrospinal fluid testing.

The company’s announcement also points to a theme that has been emerging across Alzheimer’s research and drug development: pairing disease-modifying treatments with more scalable diagnostic approaches. If blood tests can more consistently identify people in the appropriate stage of disease, that can influence trial enrollment and, over time, real-world treatment decision-making.

Because the July 11 report is a market-news item rather than an official AAIC abstract or a company slide set, it does not include the specific datasets that investors typically look for, such as the duration of follow-up, the size of the safety population, or the magnitude and statistical significance of any efficacy measures. Lilly also did not disclose in the reported summary any start date for dosing timelines or whether the “long term” information comes from extension periods or longer planned follow-up.

AAIC is one of the largest global scientific meetings for Alzheimer’s research. For drug makers, presenting at AAIC can serve multiple purposes, including reinforcing the evidence base for regulatory discussions, informing clinical practice expectations, and shaping how clinicians interpret treatment benefits and risks.

For Lilly specifically, additional Kisunla data at AAIC could matter because Alzheimer’s trials have become increasingly sensitive to questions about durability of effect and tolerability over time, including treatment-associated adverse events. Updated safety information, even without new efficacy claims, can influence how clinicians weigh continuing therapy and managing risk.

What remains uncertain from the reported preview is exactly which analyses Lilly will highlight, including whether the Alzheimer’s blood-test results are tied to patient selection, response monitoring, or an evaluation of the test’s performance against other diagnostic standards. AAIC abstracts and Lilly’s own conference materials will be the next place to look for those details, including methodology and any limitations the company notes.